Irving joined Five Prime in August 2017 as the vice president of research. Prior to joining Five Prime, he was at CytomX Therapeutics, where he most recently served as vice president of cancer immunology.
Irving received a Ph.D. in Immunology from the University of California, San Francisco and a B.A. in Physiology from the University of California, Berkeley.
Five Prime Therapeutics discovers and develops therapeutics to improve the lives of patients with serious diseases.
The company's comprehensive extracellular protein discovery platform positions it to explore pathways in cancer, inflammation, and their intersection in immuno-oncology, an area of growing focus of the company's R and D activities.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval